Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 12 5 versus BENZPHETAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 12 5 versus BENZPHETAMINE HYDROCHLORIDE.
ADDERALL 12.5 vs BENZPHETAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Benzphetamine is a sympathomimetic amine that acts as a central nervous system stimulant. It primarily works by promoting the release of norepinephrine and dopamine from presynaptic nerve terminals in the brain, which leads to appetite suppression and increased energy expenditure.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
25-50 mg orally once daily, may increase by 25 mg increments at weekly intervals; maximum 100 mg/day.
None Documented
None Documented
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Benzphetamine has a long elimination half-life of 10-16 hours (up to 20 hours in some individuals). Its active metabolites (amphetamine and methamphetamine) have half-lives of 10-12 hours and 9-11 hours, respectively. Steady state is reached within 3-4 days. The long half-life supports once-daily dosing but carries risk of accumulation with renal impairment.
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is pH-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
Primarily renal (approximately 70-90% of the dose excreted unchanged in urine, with the remainder as metabolites including amphetamine and methamphetamine). Fecal excretion is minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant